Survivorship Concerns following treatment for High Grade Glioma
Research type
Research Study
Full title
Survivorship Concerns following treatment for High Grade Glioma
IRAS ID
204696
Contact name
Cressida Lorimer
Contact email
Sponsor organisation
Brighton and Sussex NHS Trust
Duration of Study in the UK
0 years, 8 months, 1 days
Research summary
As our treatment of cancer continues to improve, we are seeing an increasing number of patients living with and beyond their cancer diagnosis. Within the field of neuro oncology, the commonest primary malignant brain tumour is a High Grade Glioma (HGG) and prognosis has historically been poor with median survival in the region of 12-15 months. However there is a small proportion of patients (around 5-10%) who are living longer. These patients are at risk of experiencing some of the later side effects of the treatment they received. There is a growing interest in the survivorship concerns of these patients and the impact of these side effects on quality of life.
We aim to assess the current survivorship concerns amongst patients 2 or more years after their diagnosis and treatment for an HGG in our centre. Patients will be identified from hopsital records and, if consenting, asked to complete 2 questionnaires prior to their routine clinic visit. These will assess quality of life, social situation and mood alongside known potential long term side effects of treatment.
Results of these questionnaires will be collated alongside clinical details from the clinic visit and analysed for trends in certain domains of long term side effects and survivorship concerns. From the results of these, we aim to assess whether there are certain areas where increased intervention or support could be considered.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
16/EM/0293
Date of REC Opinion
20 Jul 2016
REC opinion
Further Information Favourable Opinion